| Chemical Properties | Back Directory | [storage temp. ]
Desiccate at -20°C | [solubility ]
Soluble to 100 mM in water and to 100 mM in DMSO | [form ]
Powder | [color ]
Off-white to light yellow |
| Hazard Information | Back Directory | [Uses]
NAS-181 is a selective r5-HT1B antagonist. Active in vivo. | [in vivo]
NAS181 (1-10 mg/kg; s.c.) dose-dependently increases acetylcholine (ACh) release in the frontal, ventral hippocampus cortex and VHipp[1].
NAS181 (20 mg/kg; s.c.) enhances the 5-HT turnover in four rat brain regions (hypothalamus, hippocampus, striatum, and frontal cortex) with about 40%[1].
NAS181 (3 mg/kg; s.c.) produces a significant increase in the number of wet dog shakes in rats[1].
| Animal Model: | Adult male Sprague-Dawley rats (250-300 g) | | Dosage: | 1, 5, 10 mg/kg | | Administration: | S.c. in the scruff of the neck | | Result: | Increased the ACh release in the frontal cortex, reaching the maximal value of 500% of the control group within 80 min after the injection of the highest dose.
Increased the ACh releases in VHipp with a maximum of 230% of the control values at 80 min after the injection of the highest dose.
|
| [IC 50]
Rat 5-HT1B Receptor: 47 nM (IC50) | [storage]
Desiccate at -20°C |
|
|